Biological properties of recombinant α-interferons

40th Anniversary of the discovery of interferons

Lawrence Pfeffer, Charles A. Dinarello, Ronald B. Herberman, Bryan R.G. Williams, Ernest C. Borden, Ronald Bordens, Mark R. Walter, Tattanahalli L. Nagabhushan, Paul P. Trotta, Sidney Pestka

Research output: Contribution to journalReview article

430 Citations (Scopus)

Abstract

IFNs were first described as potent antiviral agents 40 years ago, and recombinant IFN-α(2a) and IFN-α(2b) were approved for the treatment of hairy cell leukemia just 11 years ago. Today, α-IFNs are approved worldwide for the treatment of a variety of malignancies and virologic diseases. Although the exact mechanism of action of IFN-α in the treatment of such diseases is not fully understood, many advances have been made in the characterization of the physicochemical and diverse biological properties of this highly pleiotropic cytokine. Here we review recent developments in our understanding of the antiviral and immunoregulatory properties of IFN-α, the nature of the multisubunit IFN-α receptor, and the molecular mechanisms of signal transduction. Where available, we have included comparative data on recombinant α-IFNs derived from both naturally occurring and nonnaturally occurring synthetic genes. We also review clinical data and data on the side effects and antigenicity of different sources of recombinant α-IFNs in humans. These latter topics are of clinical interest, because they may potentially affect the efficacy of these various products. Hopefully, what is already known about IFN will prompt further exploration into the mechanism(s) of action of IFN-α and thus deliver new applications for this prototypic cytokine, whose full therapeutic potential is yet to be realized.

Original languageEnglish (US)
Pages (from-to)2489-2499
Number of pages11
JournalCancer Research
Volume58
Issue number12
StatePublished - Jun 15 1998

Fingerprint

Anniversaries and Special Events
Interferons
Antiviral Agents
Cytokines
Synthetic Genes
Hairy Cell Leukemia
Signal Transduction
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Pfeffer, L., Dinarello, C. A., Herberman, R. B., Williams, B. R. G., Borden, E. C., Bordens, R., ... Pestka, S. (1998). Biological properties of recombinant α-interferons: 40th Anniversary of the discovery of interferons. Cancer Research, 58(12), 2489-2499.

Biological properties of recombinant α-interferons : 40th Anniversary of the discovery of interferons. / Pfeffer, Lawrence; Dinarello, Charles A.; Herberman, Ronald B.; Williams, Bryan R.G.; Borden, Ernest C.; Bordens, Ronald; Walter, Mark R.; Nagabhushan, Tattanahalli L.; Trotta, Paul P.; Pestka, Sidney.

In: Cancer Research, Vol. 58, No. 12, 15.06.1998, p. 2489-2499.

Research output: Contribution to journalReview article

Pfeffer, L, Dinarello, CA, Herberman, RB, Williams, BRG, Borden, EC, Bordens, R, Walter, MR, Nagabhushan, TL, Trotta, PP & Pestka, S 1998, 'Biological properties of recombinant α-interferons: 40th Anniversary of the discovery of interferons', Cancer Research, vol. 58, no. 12, pp. 2489-2499.
Pfeffer L, Dinarello CA, Herberman RB, Williams BRG, Borden EC, Bordens R et al. Biological properties of recombinant α-interferons: 40th Anniversary of the discovery of interferons. Cancer Research. 1998 Jun 15;58(12):2489-2499.
Pfeffer, Lawrence ; Dinarello, Charles A. ; Herberman, Ronald B. ; Williams, Bryan R.G. ; Borden, Ernest C. ; Bordens, Ronald ; Walter, Mark R. ; Nagabhushan, Tattanahalli L. ; Trotta, Paul P. ; Pestka, Sidney. / Biological properties of recombinant α-interferons : 40th Anniversary of the discovery of interferons. In: Cancer Research. 1998 ; Vol. 58, No. 12. pp. 2489-2499.
@article{2f1db111f07041439fe5a1aae199d40c,
title = "Biological properties of recombinant α-interferons: 40th Anniversary of the discovery of interferons",
abstract = "IFNs were first described as potent antiviral agents 40 years ago, and recombinant IFN-α(2a) and IFN-α(2b) were approved for the treatment of hairy cell leukemia just 11 years ago. Today, α-IFNs are approved worldwide for the treatment of a variety of malignancies and virologic diseases. Although the exact mechanism of action of IFN-α in the treatment of such diseases is not fully understood, many advances have been made in the characterization of the physicochemical and diverse biological properties of this highly pleiotropic cytokine. Here we review recent developments in our understanding of the antiviral and immunoregulatory properties of IFN-α, the nature of the multisubunit IFN-α receptor, and the molecular mechanisms of signal transduction. Where available, we have included comparative data on recombinant α-IFNs derived from both naturally occurring and nonnaturally occurring synthetic genes. We also review clinical data and data on the side effects and antigenicity of different sources of recombinant α-IFNs in humans. These latter topics are of clinical interest, because they may potentially affect the efficacy of these various products. Hopefully, what is already known about IFN will prompt further exploration into the mechanism(s) of action of IFN-α and thus deliver new applications for this prototypic cytokine, whose full therapeutic potential is yet to be realized.",
author = "Lawrence Pfeffer and Dinarello, {Charles A.} and Herberman, {Ronald B.} and Williams, {Bryan R.G.} and Borden, {Ernest C.} and Ronald Bordens and Walter, {Mark R.} and Nagabhushan, {Tattanahalli L.} and Trotta, {Paul P.} and Sidney Pestka",
year = "1998",
month = "6",
day = "15",
language = "English (US)",
volume = "58",
pages = "2489--2499",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Biological properties of recombinant α-interferons

T2 - 40th Anniversary of the discovery of interferons

AU - Pfeffer, Lawrence

AU - Dinarello, Charles A.

AU - Herberman, Ronald B.

AU - Williams, Bryan R.G.

AU - Borden, Ernest C.

AU - Bordens, Ronald

AU - Walter, Mark R.

AU - Nagabhushan, Tattanahalli L.

AU - Trotta, Paul P.

AU - Pestka, Sidney

PY - 1998/6/15

Y1 - 1998/6/15

N2 - IFNs were first described as potent antiviral agents 40 years ago, and recombinant IFN-α(2a) and IFN-α(2b) were approved for the treatment of hairy cell leukemia just 11 years ago. Today, α-IFNs are approved worldwide for the treatment of a variety of malignancies and virologic diseases. Although the exact mechanism of action of IFN-α in the treatment of such diseases is not fully understood, many advances have been made in the characterization of the physicochemical and diverse biological properties of this highly pleiotropic cytokine. Here we review recent developments in our understanding of the antiviral and immunoregulatory properties of IFN-α, the nature of the multisubunit IFN-α receptor, and the molecular mechanisms of signal transduction. Where available, we have included comparative data on recombinant α-IFNs derived from both naturally occurring and nonnaturally occurring synthetic genes. We also review clinical data and data on the side effects and antigenicity of different sources of recombinant α-IFNs in humans. These latter topics are of clinical interest, because they may potentially affect the efficacy of these various products. Hopefully, what is already known about IFN will prompt further exploration into the mechanism(s) of action of IFN-α and thus deliver new applications for this prototypic cytokine, whose full therapeutic potential is yet to be realized.

AB - IFNs were first described as potent antiviral agents 40 years ago, and recombinant IFN-α(2a) and IFN-α(2b) were approved for the treatment of hairy cell leukemia just 11 years ago. Today, α-IFNs are approved worldwide for the treatment of a variety of malignancies and virologic diseases. Although the exact mechanism of action of IFN-α in the treatment of such diseases is not fully understood, many advances have been made in the characterization of the physicochemical and diverse biological properties of this highly pleiotropic cytokine. Here we review recent developments in our understanding of the antiviral and immunoregulatory properties of IFN-α, the nature of the multisubunit IFN-α receptor, and the molecular mechanisms of signal transduction. Where available, we have included comparative data on recombinant α-IFNs derived from both naturally occurring and nonnaturally occurring synthetic genes. We also review clinical data and data on the side effects and antigenicity of different sources of recombinant α-IFNs in humans. These latter topics are of clinical interest, because they may potentially affect the efficacy of these various products. Hopefully, what is already known about IFN will prompt further exploration into the mechanism(s) of action of IFN-α and thus deliver new applications for this prototypic cytokine, whose full therapeutic potential is yet to be realized.

UR - http://www.scopus.com/inward/record.url?scp=0032526030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032526030&partnerID=8YFLogxK

M3 - Review article

VL - 58

SP - 2489

EP - 2499

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -